The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer

Pyrotinib (PYR) is a pan-HER kinase inhibitor that inhibits signaling via the RAS/RAF/MEK/MAPK and PI3K/AKT pathways. In this study, we aimed to investigate the antitumor efficacy of pyrotinib combined with adriamycin (ADM) and explore its mechanisms on HER2(+) breast cancer. We investigated the eff...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Wang, Chaokun, Deng, Shuzhen, Chen, Jing, Xu, Xiangyun, Hu, Xiaochen, Kong, Dejiu, Liang, Gaofeng, Yuan, Xiang, Li, Yuanpei, Wang, Xinshuai
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177085/
https://ncbi.nlm.nih.gov/pubmed/34094901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.616443
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares